Abstract
The aim of this study was to evaluate the influence of heated heliox-driven nebulizer therapy on pulmonary hypertension and arterial oxygenation in patients with BA. 40 patients with severe and 40 patients with moderate exacerbation of nonatopic BA were recruited for the study. They received Berodual and Pulmicort delivered by a nebulizer powered by either heated heliox (He/O2 = 80/20; T = 45°C; 20 patients with severe exacerbation (Gr.1), 20 patients with moderate exacerbation (Gr.2)) or air (20 patients with severe exacerbation (Gr.3), 20 patients with moderate exacerbation (Gr.4)) in 10 procedures. We studied systolic pulmonary artery pressure (sPAP) and arterial oxygenation (PaO2). After 10-days treatment patients in Gr.1 had more increasing of PaO2 (58,5±8,2 mmHg vs 70,9±10,0 mmHg, p<0,05, increased by 21%), and more reduction of sPAP (41,0±8,5 mm Hg vs 37,5±5,9 mm Hg, p<0,05, decreased by 9%), compared to Gr.3: PaO2 (57,9±11,1 mmHg vs 63,0±7,0 mmHg, p>0,05, increased by 9%), sPAP (40,6±7,3 mm Hg vs 38,3±6,4 mm Hg, p>0,05, decreased by 6%). After 10-days treatment patients in Gr.2 had a significant improvement of PaO2 (64,8±6,4 mmHg vs 73,7±4,2 mmHg, p<0,05, increased by 14%), and a meaningful reduction of sPAP (31,±4,2 mm Hg vs 27,7±3,4 mm Hg, p<0,05, decreased by 13%), compared to Gr.4: PaO2 (65,0±8,2 mmHg vs 72,0±7,0 mmHg, p>0,05, increased by 11%), sPAP (34,0±9,5 mm Hg vs 31,4±8,4 mm Hg, p>0,05, decreased by 7%). Thus, complex therapy with heated HDN in patients with severe and moderate BA increases the efficiency of treatment and leads to meaningful reduction of hypoxemia and pulmonary hypertension.
- © 2011 ERS